INTRODUCTION
Glioblastoma (GBM), also known as grade 4 astrocytoma, is the most aggressive intrinsic brain tumor in adults and continues to be associated with extremely poor outcomes. 1 Evidence to date indicates that the cells of origin for GBM may be either neural stem cells or their more differentiated progeny. [2] [3] [4] Most GBMs arise with no prior clinical history of a precursor lesion and are referred to as primary or de novo GBMs. A minority of GBM cases, known as secondary GBMs, develop from lower-grade astrocytomas or oligodendrogliomas and bear different genomic abnormalities than primary GBM. [5] [6] [7] Despite recent studies suggesting that molecular subsets of GBM differ in response to current treatments, 8, 9 standard treatment for all patients with primary GBM 10 is a regimen combining radiation and temozolomide. The recent identification of R132 mutations in isocitrate dehydrogenase 1 (IDH1 R132MUT ) in the majority of low-grade gliomas and secondary GBMs, with relative exclusion from primary GBMs, implicates IDH1
R132MUT as a defining marker and key oncogenic event for GBMs
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
that evolve from lower-grade glioma. [11] [12] [13] [14] [15] [16] Herein, we sought to develop a detailed portrait of untreated GBMs arising with IDH1
R132MUT
with the aim of gaining insights into the manner in which IDH1 R132MUT gliomas develop and to determine whether IDH1
GBM is a distinct disease entity.
PATIENTS AND METHODS
The focus of our investigation is 618 patients with newly diagnosed untreated primary (de novo) GBMs (cohorts A through F) and 235 patients with newly diagnosed untreated lower-grade diffuse gliomas (cohorts G and H). Patients with GBM included two cohorts compiled for this investigation (cohorts A and B), plus patients associated with previously reported studies [17] [18] [19] [20] (cohorts C through F). Sequence analysis of IDH1 R132 and p53 R273 included 105 additional samples of diffuse glioma (cohort I). A summary of patient cohorts is provided in Table 1 . Additional details regarding Methods and patient cohorts are provided in the Data Supplement.
RESULTS

IDH1
R132MUT GBMs Are Phenotypically Distinct To characterize IDH1 R132MUT and IDH1
R132
-wild type (IDH1 R132WT ) GBMs in the absence of confounding treatment effects, we pursued a comparison within treatment-naive patients with primary GBM. From 618 de novo GBMs, we identified 49 IDH1 R132MUT tumors, all of which occurred in adults. Within adult patients, we confirmed that IDH1 R132MUT GBMs manifest longer overall survival 12,13,16,21 (Appendix Fig A1A, online only) and showed more frequent promoter methylation of O 6 -methylguanine-DNA methyltransferase (MGMT) 8, 21, 22 as illustrated in Figure 1A . Histologic characterization of a sampling of IDH1 R132MUT and IDH1 R132WT GBMs demonstrated similar levels of cell proliferation on the basis of MIB-1 staining (Data Supplement), but revealed a lesser extent of necrosis in IDH1 R132MUT GBMs ( Fig 1A) and a nonsignificant trend toward less frequent occurrence of vascular abnormalities (Fig 1A) . Consistent with a previous report, 12 examination of an expanded series of samples revealed a statistically significant, albeit modest, increase in the percentage of cells with oligodendroglial morphology in
IDH1
R132MUT GBMs (Fig 1A) . To examine whether tumors in our series of GBMs harbored the co-deletion of chromosome arms 1p/19q commonly observed in oligodendrogliomas, we assessed DNA copy number alterations by using array comparative genomic hybridization in a series of samples and found that a minority of IDH1
R132MUT
GBMs (two of eight) and none of the IDH1 R132WT GBMs (zero of 13) displayed 1p/19q co-deletion (Appendix Fig A1B) . There was a striking difference between the two GBM subsets regarding loss of chromosome 10; this alteration was absent in all IDH1 R132MUT GBMs but was present in all but one sample of IDH1 R132WT GBM (Appendix Fig A1B) .
By using previously defined parameters, 23 we examined available preoperative cranial magnetic resonance images. Consistent with our histologic findings, detection of necrosis was less frequent in IDH1 R132MUT GBMs; moreover, IDH1 R132MUT GBMs exhibited more frequent non-enhancing tumor component, larger size at diagnosis, lesser extent of edema, and increased prevalence of cystic and diffuse components ( Fig 1B and Appendix Fig A1C) . In addition, the IDH1 R132MUT GBMs demonstrated greater frequency of contact with brain ventricles, although interpretation of this finding may be confounded by the larger size of IDH1 R132MUT GBMs (Appendix Fig  A1C) . Overall, the radiographic and histologic features that distinguish IDH1 R132MUT GBMs resemble characteristics of lower-grade gliomas and are consistent with a less aggressive clinical course.
Restricted Gene Expression of IDH1
R132MUT GBMs By examining transcriptional signatures of both the newly diagnosed high-grade astrocytomas in this investigation and The Cancer Genome Atlas (TCGA) primary GBM data set, we found that the majority of IDH1 R132MUT tumors express the Proneural 17 subtype signature (Fig 2A and Appendix Fig A2A, online only) . This Proneural signature has previously been reported as a positive prognostic indicator 17 and is substantially similar to the TCGA Proneural signature associated with IDH1 R132MUT GBMs that resembles the signature of oligodendroglia. 9 A minority of IDH1 R132MUT GBMs possessed the Proliferative signature, and none possessed the Mesenchymal signature associated with angiogenesis and poor outcome 17 (Fig 2A and  Appendix Fig A2A) . In contrast, IDH1
R132WT GBMs displayed all 24 to compare expression profiles of the human tumors with a published embryonic mouse forebrain gene expression data set, 25 we found that global expression profiles of IDH1 R132WT GBMs resemble mouse neural stem cells, and IDH1
R132MUT GBMs resemble lineage-committed neural precursors (AGDEX, ϩ0.147; P Ͻ .004; Data Supplement). A separate hierarchical clustering analysis that used the genes most differentially expressed between IDH1
R132MUT and IDH1 R132WT GBMs reveals similarity of IDH1 R132MUT samples to normal fetal or adult brain parenchyma and similarity of IDH1 R132WT GBMs to cultured adult neural stem cells 26 ( Fig 2B) . Because both fetal and adult brain samples are enriched for differentiating or mature neural cell types, these findings underscore the greater similarity of IDH1
R132MUT
GBMs to lineage-committed neural cells than to stem cells.
IDH1 R132MUT GBMs Are Spatially and Temporally Restricted
Tabulating the location of IDH1 R132MUT and IDH1
R132WT
GBMs, we found a striking predominance of frontal lobe involvement of IDH1 R132MUT GBMs that contrasts with the more widespread distribution of IDH1
R132WT GBMs ( Fig 3A) . Regardless of histologic subtype, IDH1
R132MUT gliomas displayed a nearly identical percentage of frontal lobe involvement (Appendix Figs A3A-A3C, online only).
Overlay of tumor areas from a series of all available IDH1
R132MUT
GBMs with digitized pretreatment magnetic resonance images confirmed the high frequency of frontal lobe involvement, whereas overlay of a random sampling of IDH1 R132WT tumors failed to demonstrate any frequently involved regions (Appendix Fig A3D) . By performing a voxel-wise Fisher's exact test to isolate the area of differential involvement, we found that IDH1 R132MUT GBMs were distributed at increased frequency in the area of the frontal lobe surrounding the rostral extension of the lateral ventricle ( Fig 3B) .
By examining tumor genotype as a function of age for both GBMs and grade 3 astrocytoma (anaplastic astrocytoma), we found that the relative frequency of IDH1 R132MUT tumors rises sharply in the third decade of life and decreases in the fourth or fifth decade (Fig 3C) . Thus, relative to IDH1 R132WT tumors, IDH1 R132MUT tumors appear to arise at greatest frequency within a more restricted time period. Interestingly, within adult GBMs, a significant difference in sex ratios was seen as a function of IDH1 R132 status, consistent with previous reports of trends for a greater fraction of female patients with secondary versus primary GBM 27,28 (Appendix Fig A3E) .
IDH1 R132MUT GBMs Show Preponderance of Template Strand Mutation in IDH1 and Coding Strand Mutation in p53
In agreement with previous reports, 13 ,16,29 our data showed a higher frequency of p53 mutation in IDH1
R132MUT versus IDH1 R132WT high-grade astrocytomas (Appendix Fig A4A, online  only) . Consistent with the well-documented propensity for CϾT mutation at cytosine phosphate guanine (CpG) sites, 30 data from our sample set showed that the most common mutations in both p53 and IDH1 are at Arg residues encoded by the codon CGT (IDH1 R132 and p53
R273
; Figs 4A and 4B). For both IDH1 R132 and p53
, CϾT mutations on template and coding strands will result in substitutions of His or Cys, respectively. By sequencing an expanded series of grades 2 to 4 gliomas for these codons in IDH1 and p53, we found, within IDH1 R132MUT gliomas, a marked and unexpected contrast between the prevalence of Cys and His substitutions in the two proteins (P Ͻ .001 with Fisher's exact test; Fig 4A) . Given that the probability for mutation is highest for CϾT mutations, we deduce that the mutation pattern observed in tumors with mutations in both IDH1 R132 and p53 R273 is most likely to have occurred by strong selection for IDH1 and p53 mutations on the template versus on the coding strands, respectively (Fig 4B) . These findings suggest that if both IDH1
R132H and p53
R273C mutations occur as CϾT mutations in a nonproliferating cell, mutant IDH1 protein will be expressed immediately, whereas mutant p53 protein will not occur until after DNA replication. The predominance of p53 R273C in the IDH1 R132MUT tumors contrasts with the preference for p53 R273H in the IDH1 R132WT tumors (P Ͻ .005 with Fisher's exact test).
IDH1
R132MUT GBMs Demonstrate CpG Island Methylator Phenotype, Focal EGFR Amplification, and Focal PTEN Loss
To identify other molecular aberrations that may cooperate with IDH1 R132MUT in gliomagenesis, we performed a CpG island methylation profiling analysis on a subset of IDH1 R132MUT and IDH1
R132WT
GBMs and found a distinct pattern of CpG island hypermethylation that was detected in all GBMs and lower-grade gliomas with IDH1 R132MUT but was absent from nearly all IDH1 R132WT gliomas (Appendix Fig A4B) . The methylation pattern in IDH1
R132MUT
GBMs shows similarity to the recently reported CpG island methylator phenotype (CIMP) found to be closely associated with IDH1
R132MUT gliomas 31 and adds to the previous suggestion that these coordinated methylation changes occur early in the development of IDH1 R132MUT tumors. Array comparative genomic hybridization analysis and/or fluorescent in situ hybridization revealed lower frequencies of PTEN loss and fewer instances of EGFR amplification in IDH1 R132MUT GBMs versus IDH1
R132WT GBMs (Appendix Fig A4C; Figs A4C and A4D) . The focality of copy number alterations for EGFR and PTEN in the IDH1 R132MUT GBMs points to the likelihood that these are late events in the evolution of these tumors.
DISCUSSION
The development of novel therapeutic regimens for human malignancies, particularly those involving targeted therapy, is greatly facilitated by methods for identifying clinically meaningful disease subsets. To gain greater understanding of the utility of IDH1
R132MUT as a marker in diffuse glioma, we have conducted a comprehensive analysis of the features of newly diagnosed cases of primary GBMs arising with and without IDH1
R132MUT
. Our results indicate that, although histologically similar, IDH1
R132MUT and IDH1 R132WT GBMs differ in their demographic, anatomic, phenotypic, epigenetic, and genomic presentation and follow a different clinical course, supporting a model of two disease entities that most likely arise from separate cell types of origin as the result of largely nonoverlapping sets of molecular events (Fig 5) . Increased understanding of the cell of origin and molecular evolution of IDH1 R132MUT GBM may aid in development of therapeutic strategies for this tumor type by yielding insights into the biology of these lesions and facilitating the development of animal models.
Our analysis demonstrates that the phenotypic features that distinguish IDH1
R132MUT from IDH1 R132WT GBMs include better outcome, predominance of frontal lobe location, presentation and R132WT GBMs (WT) show similarity to human adult neural stem cells for experimentation (HANSE), whereas IDH1
R132MUT GBMs (MUT) show similarity to fetal/adult brain tissue (FETAL, ADULT). R132MUT and IDH1 R132WT GBM add to the features that suggest different etiologies of the two disease entities.
Origin and Evolution of IDH1 Mutant Glioblastoma
A key finding of this investigation is the discovery of a constellation of restricted phenotypic, spatial, and temporal features of IDH1 R132MUT GBMs that is consistent with origin from a non-stemcell neural precursor pool. By revealing the exclusion of Mesenchymal signature as an absolute feature of IDH1 R132H gliomas, our results extend earlier reports of an association between IDH1 mutation and Proneural gene expression. 9, 32 This observation, and the closer resemblance of IDH1
R132MUT GBM transcriptional signatures to those of brain tissue rather than of stem cells suggests that IDH1
R132MUT GBM cells do not retain the capability to generate progeny with a broad range of transcriptional profiles.
Although the restriction of IDH1 R132MUT GBM gene expression signatures may be a consequence of the actions of IDH1
R132MUT
, taken with the spatial and temporal homogeneity of IDH1 R132MUT GBM presentation, this finding suggests that the cell of origin for IDH1 R132MUT GBMs is a neural precursor population with limited differentiation potential that is most abundant during a specific stage and location in forebrain development. Our area of differential involvement analysis demonstrates a strong propensity for IDH1 R132MUT gliomas to occur in the frontal lobe, specifically in the area surrounding the rostral extension of the lateral ventricles, indicating this region as a likely location of the cell of origin for many IDH1 R132MUT gliomas. Consistent with our findings, predominance of frontal lobe location has been reported in oligodendrogliomas with 1p/19q co-deletion, 33,34 a tumor type now known to carry IDH1 mutation at high frequency. 13, 14, 29 Previous studies 13, 15, 16, 21, 35, 36 indicate that although the median age of patients with IDH1
R132MUT GBM is younger than that for IDH1 R132WT GBM, IDH1 R132MUT is rare in the pediatric population. By using logistic regression to overcome the limitations of patient sampling, we were able to determine that the relative probability of a tumor harboring IDH1
R132MUT abruptly increases around age 20 and begins to decrease a decade later. This raises the possibility that the cell type of origin for IDH1 R132MUT gliomas is most abundant and permissive during a limited developmental time window, possibly coinciding with remodeling of prefrontal cortex in adolescence. 37, 38 Our findings that Proneural gene expression and increased oligodendroglial histology are associated with IDH1
GBMs are consistent with an oligodendroglial progenitor cell type of origin, and several studies lend support for oligodendroglial progenitor cells as a cell type of origin for glioma.
39-44
Given the strong correlation we confirmed between CIMP and IDH1 mutation, we propose that CIMP is also an early and critical event in the development of IDH1 R132MUT gliomas. Recent studies 45, 46 indicating that IDH1 mutation acts to inhibit a class of alpha-ketoglutarate-dependent enzymes, including proteins that catalyze histone demethylation and hydroxylation of methylated DNA, support the possibility that IDH1 mutation can initiate oncogenesis by inducing an epigenetic block to differentiation in a specific population of CNS cells poised at a particular developmental state. This hypothesis explains the homogeneity in presentation of IDH1
R132MUT gliomas and suggests the possibility that these lesions might show sensitivity to therapeutic regimens with differentiating agents.
Several investigations 13, 16, 18 demonstrate that most IDH1 R132MUT astrocytomas harbor mutations of p53, and one study 12 revealed instances in which IDH1 mutation was apparent before the appearance of p53 mutation. Our findings reveal the existence of a mechanism that is capable of ensuring sequential appearance of IDH1 mutant protein before p53 mutant protein, regardless of the order in which the mutations occur. Specifically, our sequencing data on IDH1 and p53 provides evidence for strand asymmetry of CpG mutations, 47 demonstrating a strong preponderance of presumed CϾT mutations on template versus coding strand for IDH1 R132 and p53
R273
, respectively.
Although mutation of IDH1 on the template strand permits immediate translation of IDH1 mutant protein, mutation of p53 R273 on the coding strand allows the appearance of p53 mutant protein only after DNA replication. Thus, in a quiescent cell, the pattern of mutations we observed at high frequency in IDH1 mutant glioma will result in appearance of IDH1 mutant protein to be followed by p53 mutant protein only after a cycle of DNA replication. The preferred substitutions seen in gliomas harboring mutations at both IDH1 R132 and p53 R273 stand in stark contrast to the substitution pattern in cancers with mutations in only one of these genes. Specifically, for IDH1 R132 , the preferred substitution in acute myeloid leukemia is Cys, 48 
Our analysis suggests a model in which IDH1
R132MUT GBMs arise in a stepwise fashion as the result of a series of sequenced molecular alterations that cooperate with normal developmental events (Fig 5 and Data Supplement). We propose that although IDH1 R132MUT , induction of CIMP, and p53
R273MUT often occur in a quiescent neural stem cell, tumors arise only from lineage-committed progeny following a wave of proliferation related to forebrain maturation that triggers appearance of mutant p53 protein and loss of cell cycle control. This oncogenic process results in a low-grade glioma that subsequently acquires additional genomic alterations that promote malignant transformation to GBM. Previous studies 11, 14, 52 provide strong evidence that PTEN loss via loss of chromosome arm 10q is an event that occurs during transition to secondary GBM. Model comparing glioblastomas (GBMs) arising with and without mutations in isocitrate dehydrogenase 1 (IDH1) at R132. We propose that the IDH1 R132MUT GBM pathway (left) is initiated by the occurrence of IDH1 mutation and resultant CpG island methylator phenotype (CIMP) in a quiescent neural progenitor residing in the frontal lobe. Although p53 mutation can be present during this time, expression of p53 mutant protein ensues only after expansion of this progenitor pool during late adolescence or early adulthood. According to the proposed model, glioma formation along the IDH1 R132MUT pathway requires the ordered appearance of IDH1 mutant protein and CIMP, followed by p53 mutant protein (or 1p/19q co-deletion 11 ). Tumors along this pathway arise from a spatially and temporally restricted neural progenitor population and most frequently maintain a Proneural gene expression signature. Transformation to IDH1
R132MUT GBM requires EGFR amplification (amp), PTEN deletion, or other genomic alterations. In contrast, in the IDH1 R132WT GBM pathway (right), EGFR amplification, and PTEN loss frequently act in concert to drive GBM formation from a cell population that maintains the ability to adopt a Mesenchymal gene expression signature. chr7ϩ, chromosome 7 gain; chr10Ϫ, chromosome 10 loss. IDH1MUT, IDH1
R132MUT ; IDH1WT, IDH1
R132WT
.
GBMs are consistent with the proposal that these events occur during the evolution of lower-grade IDH1 R132MUT glioma to GBM. In our model, the production of IDH1 mutant protein is the initial event in an orchestrated process that leads to the stepwise emergence of a distinct GBM entity that has a less aggressive clinical course than other GBMs. In contrast to the heterogeneous presentation of most GBMs, IDH1
R132MUT GBMs arise at high frequency in early adult life as frontal lobe lesions with a constellation of radiographic, histologic, and transcriptional features that relates these lesions to the lower-grade diffuse gliomas from which we contend they arise. This investigation adds to a growing body of data that suggests that histologically similar brain tumors may represent distinct disease entities arising as a result of vulnerability of different stem-cell and progenitor populations to particular oncogenic alterations.
24,53,54
IDH1
R132MUT glioma may be an especially interesting example of the dependence of oncogenesis on normal developmental processes, because the cell of origin we propose may be uniquely abundant in human brain. 
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